ProQR to Start Clinical Trial of QR-110 in Leber’s Congenital Amaurosis Type 10 Patients

May 12, 2017: By Jon Swedien

ProQRThe US FDA has given clearance to ProQR Therapeutics’ investigational new drug application for QR-110, a proposed treatment for Leber’s congenital amaurosis Type 10 (LCA 10) patients, the Netherlands company announced April 27.

ProQR said it intends to move forward with a Phase I/II open-label trial to assess the safety, tolerability, pharmacokinetics, and efficacy of multiple administrations of QR-110 in one eye of each patient. ProQR said the trial will include six adults and six children with LCA 10.

Topline results are expected in 2018.

QR-110 is a first-in-class RNA-based oligonucleotide designed to address the underlying cause of LCA 10, a mutation in the CEP290 gene. It is intended to be administered through intravitreal injections in the eye. QR-110 has been granted orphan drug designation in the US and European Union, the company said.

LCA 10 leads to progressive loss of vision, causing most patients to lose their sight in the first few years of life. There are no approved treatments or products in clinical development that treat the underlying cause of the disease, ProQR said.

ProQR is focused on RNA medicines for the treatment of severe genetic rare diseases such as LCA 10, cystic fibrosis, and dystrophic epidermolysis bullosa.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Refocus Completes PMA Application for VisAbility as Treatment for Presbyopia

Novaliq’s NovaTears+Omega-3 Approved in Europe for Dry Eye

CooperVision Acquires Paragon Vision Sciences for $80 Million

AYOXXA Biosystems Launches Test for Biomarkers in Retinal Disease

Glaukos Announces New Patent for Glaucoma Stent Implanted in Schlemm’s Canal

Fortress Biotech Forms Tamid Bio Subsidiary; Lead Candidate is Ophthalmic Gene Therapy for MPS I

Samsung Launches App that Adjusts QLED TV Settings for Color-blind Viewers

Solar Eclipse Burns Crescent Wound in Woman’s Unprotected Retina

US Judge Refuses to Dismiss Allergan Suit against Imprimis

BioLight Sells IOPtima to Chengdu Kanghong Pharmaceutical Group for $56 Million

Regeneron Ending Eylea, Nesvacumab Combo Program

UK Retinal Drugmaker Exonate Forms Clinical Advisory Board

US FDA Approves RxSight’s Light Adjustable Lens and Light Delivery Device

EMA to Move to Amsterdam due to Brexit

First Subject Dosed in Nevakar’s Phase III Trial of NVK-002 for Myopia in Children

ProQR Doses First Patient in Phase I/II Trial for Leber’s Congenital Amaurosis 10

Aston EyeTech Raises $6.6 Million in Series A Equity Round

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022